Baxter International Hits New 52-Week Low at $16.84

Baxter International, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 16.84 on March 16, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 48.07%, contrasting sharply with the S&P 500's gain of 18.81% during the same period. The company's market capitalization stands at approximately USD 14.9 billion, with a price-to-earnings (P/E) ratio of 28.00. Baxter's financial metrics reveal a dividend yield of 1.78% and a debt-to-equity ratio of 1.23, indicating a relatively high level of debt compared to equity. The return on equity is reported at 4.23%, while the price-to-book ratio is 2.43. Baxter has faced challenges in its financial performance, with a notable decline in net sales, which fell by 26.29% to USD 2,810 million. Additionally, the company has reported negative results for the last three consecutive quarters, highlighting ongoing difficulties in its operational performance.